Amyotrophic Lateral Sclerosis (ALS) Awareness and Research: Recent Developments in Quebec

The first SLA Québec walk in Victoriaville took place Sunday at the Beaudet Reservoir, raising $1,000 to support individuals living with amyotrophic lateral sclerosis (ALS). This local initiative, which drew regional officials and supporters, contributes to a broader provincial effort during June—ALS Awareness Month—to fund research and provide resources for the approximately 600 people currently living with the disease in Quebec.

What is Amyotrophic Lateral Sclerosis?

ALS, often referred to as Lou Gehrig’s disease, is a progressive neurodegenerative condition that affects nerve cells in the brain and spinal cord. According to ALS Canada, the disease leads to the loss of muscle control, eventually impacting a person’s ability to walk, speak, eat, and breathe. While the condition affects roughly 4,000 Canadians annually, the exact cause remains unknown for the majority of cases. As noted by the Government of Quebec, the condition is fatal, with most patients experiencing a rapid decline in health within three to five years of diagnosis.

The Status of ALS Research and Treatment

For decades, medical professionals have sought effective interventions for ALS. As of 2025, the therapeutic landscape is shifting. Health Canada has approved specific treatments for patients with the SOD1 genetic mutation, a rare form of the disease that accounts for approximately 2% of total cases. For the remaining 98% of patients, clinical trials and research into neurodegenerative mechanisms remain the primary focus.

Dr. Richard Robitaille, a professor and researcher at the Université de Montréal, emphasizes that the speed of scientific discovery is currently hampered by funding structures. “The lack of stable, long-term research funding slows down our ability to understand the disease’s underlying mechanisms and develop new therapeutic approaches,” Dr. Robitaille stated. He stresses that accelerating research is a medical imperative to improve outcomes for those affected by this rapidly progressing condition.

How Funding Impacts Patient Support

Community events like the Victoriaville walk are part of a larger fundraising network organized by SLA Québec. To date, ten such marches across the province have raised over $231,000. These funds are directed toward two core objectives:

• Direct Patient Support: Providing specialized equipment, home care assistance, and emotional support to families navigating the disease.
• Research Acceleration: Financing clinical studies that seek to identify biomarkers and potential drug targets for broader ALS populations.

Frequently Asked Questions

Is ALS considered a hereditary disease?

Most cases of ALS are “sporadic,” meaning they occur randomly with no clear family history. Only about 5% to 10% of cases are “familial,” linked to specific genetic mutations passed down through families, according to the National Institute of Neurological Disorders and Stroke.

What is the current life expectancy after an ALS diagnosis?

While individual outcomes vary significantly, the majority of people diagnosed with ALS survive between two and five years after symptoms first appear. However, some individuals live for a decade or longer, depending on the progression of the disease and the level of respiratory and nutritional support received.

How can one contribute to ALS research in Quebec?

Individuals can support ongoing efforts through the SLA Québec website, which coordinates regional fundraising events, golf tournaments, and cycling initiatives throughout the year, particularly during the June awareness campaign.